| Segment information |
M. Segment
information:
The Company has two
reportable segments based on the nature of its products. R&D
Systems’ Biotechnology Division, R&D Europe, Tocris,
R&D China, BiosPacific and Boston Biochem operating segments
are included in the biotechnology reporting segment. The
Company’s biotechnology reporting segment develops,
manufactures and sells biotechnology research and diagnostic
products world-wide. The Company’s hematology reporting
segment, which consists of R&D Systems’ Hematology
Division, develops and manufactures hematology controls and
calibrators for sale world-wide. No customer of either segment
accounted for more than 10% of the Company’s consolidated net
sales for the years ended June 30, 2012, 2011 and
2010.
The accounting policies of
the segments are the same as those described in Note A. In
evaluating segment performance, management focuses on sales and
earnings before taxes.
Following is financial
information relating to the operating segments (in
thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
Year Ended
June 30, |
|
| |
|
2012 |
|
|
2011 |
|
|
2010 |
|
|
External sales
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Biotechnology
|
|
$ |
293,274 |
|
|
$ |
270,287 |
|
|
$ |
250,653 |
|
|
Hematology
|
|
|
21,286 |
|
|
|
19,675 |
|
|
|
18,394 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated net
sales
|
|
$ |
314,560 |
|
|
$ |
289,962 |
|
|
$ |
269,047 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings before
taxes
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Biotechnology
|
|
$ |
162,763 |
|
|
$ |
164,332 |
|
|
$ |
155,989 |
|
|
Hematology
|
|
|
8,002 |
|
|
|
7,222 |
|
|
|
6,869 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Segment earnings before
taxes
|
|
|
170,765 |
|
|
|
171,554 |
|
|
|
162,858 |
|
|
Other
|
|
|
(8,570 |
) |
|
|
(6,573 |
) |
|
|
(6,412 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated earnings
before taxes
|
|
$ |
162,195 |
|
|
$ |
164,981 |
|
|
$ |
156,446 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Goodwill
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Biotechnology
|
|
$ |
85,682 |
|
|
$ |
86,633 |
|
|
$ |
25,068 |
|
|
Hematology
|
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated
goodwill
|
|
$ |
85,682 |
|
|
$ |
86,633 |
|
|
$ |
25,068 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Intangible assets,
net
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Biotechnology
|
|
$ |
46,476 |
|
|
$ |
52,282 |
|
|
$ |
2,044 |
|
|
Hematology
|
|
|
0 |
|
|
|
0 |
|
|
|
0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated intangible
assets, net
|
|
$ |
46,476 |
|
|
$ |
52,282 |
|
|
$ |
2,044 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Assets
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Biotechnology
|
|
$ |
529,392 |
|
|
$ |
505,087 |
|
|
$ |
400,112 |
|
|
Hematology
|
|
|
22,135 |
|
|
|
21,046 |
|
|
|
18,543 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Segment assets
|
|
|
551,527 |
|
|
|
526,133 |
|
|
|
418,655 |
|
|
Other
|
|
|
167,797 |
|
|
|
91,537 |
|
|
|
100,161 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated
assets
|
|
$ |
719,324 |
|
|
$ |
617,670 |
|
|
$ |
518,816 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and
amortization
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Biotechnology
|
|
$ |
10,920 |
|
|
$ |
7,165 |
|
|
$ |
5,411 |
|
|
Hematology
|
|
|
411 |
|
|
|
417 |
|
|
|
340 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Segment depreciation and
amortization
|
|
|
11,331 |
|
|
|
7,582 |
|
|
|
5,751 |
|
|
Other
|
|
|
1,136 |
|
|
|
1,118 |
|
|
|
2,379 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated depreciation
and amortization
|
|
$ |
12,467 |
|
|
$ |
8,700 |
|
|
$ |
8,130 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Capital
purchases
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Biotechnology
|
|
$ |
4,021 |
|
|
$ |
2,707 |
|
|
$ |
3,885 |
|
|
Hematology
|
|
|
597 |
|
|
|
149 |
|
|
|
208 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Segment capital
purchases
|
|
|
4,618 |
|
|
|
2,856 |
|
|
|
4,093 |
|
|
Other
|
|
|
1,399 |
|
|
|
774 |
|
|
|
551 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated capital
purchases
|
|
$ |
6,017 |
|
|
$ |
3,630 |
|
|
$ |
4,644 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The other reconciling items
include the results of unallocated corporate expenses and assets,
and the Company’s share of losses from its equity method
investees.
Following is financial
information relating to geographic areas (in
thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
Year Ended
June 30, |
|
| |
|
2012 |
|
|
2011 |
|
|
2010 |
|
|
External sales
|
|
|
|
|
|
|
|
|
|
|
|
|
|
United States
|
|
$ |
172,310 |
|
|
$ |
159,857 |
|
|
$ |
148,137 |
|
|
Europe
|
|
|
90,142 |
|
|
|
83,676 |
|
|
|
78,496 |
|
|
China
|
|
|
11,378 |
|
|
|
8,299 |
|
|
|
6,792 |
|
|
Other Asia
|
|
|
25,988 |
|
|
|
24,715 |
|
|
|
22,372 |
|
|
Rest of
world
|
|
|
14,742 |
|
|
|
13,415 |
|
|
|
13,250 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total external
sales
|
|
$ |
314,560 |
|
|
$ |
289,962 |
|
|
$ |
269,047 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Long-lived
assets
|
|
|
|
|
|
|
|
|
|
|
|
|
|
United States
|
|
$ |
87,968 |
|
|
$ |
88,802 |
|
|
$ |
91,554 |
|
|
Europe
|
|
|
7,528 |
|
|
|
7,819 |
|
|
|
6,299 |
|
|
China
|
|
|
141 |
|
|
|
96 |
|
|
|
70 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total long-lived
assets
|
|
$ |
95,637 |
|
|
$ |
96,717 |
|
|
$ |
97,923 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
External sales are
attributed to countries based on the location of the
customer/distributor. Long-lived assets are comprised of land,
buildings and improvements and equipment, net of accumulated
depreciation and other assets.
|